Trial · NCT00104871

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

NCT00104871, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2014-06-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy. Trials, record NCT00104871. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00104871

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
NCT number: NCT00104871
Status: Completed
Phases: Phase 2
Enrollment: 24 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions: Bortezomib
First posted: 2005-03-04
Last updated: 2018-12-19
Results first posted: 2014-06-25

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Tumor Response Rate Assessed by RECIST	Baseline to 12 weeks	Response Rate calculated as number of participants with Complete or Partial Response divided by total participants. Baseline scan and confirmatory scans obtained 6 weeks following initial documentation of objective response using Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): \>30% decrease in sum longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Primary	Participant Tumor Response Assessed by RECIST	Baseline to 12 weeks (minimum of 4 treatment cycles (or 12 weeks))	Baseline scan and confirmatory scans obtained 6 weeks following initial documentation of objective response using Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): \>30% decrease in sum longest diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Secondary	Progression-free Survival Assessed by RECIST	At 6 months	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Objective Tumor Response Rate Assessed by RECIST	Baseline to 12 weeks	Two participants were not evaluable for response.	participants	NUMBER
PRIMARY	Participant Tumor Response Assessed by RECIST	Baseline to 12 weeks (minimum of 4 treatment cycles (or 12 weeks))	Two participants were not evaluable for response.	participants	NUMBER
SECONDARY	Progression-free Survival Assessed by RECIST	At 6 months	Two participants were not evaluable for response.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Objective Tumor Response Rate Assessed by RECIST	Bortezomib		0	participants
Participant Tumor Response Assessed by RECIST	Bortezomib	Complete Response	0	participants
Participant Tumor Response Assessed by RECIST	Bortezomib	Partial Response	0	participants
Participant Tumor Response Assessed by RECIST	Bortezomib	Stable Disease	11	participants
Participant Tumor Response Assessed by RECIST	Bortezomib	Progressive Disease	9	participants
Progression-free Survival Assessed by RECIST	Bortezomib		4	Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Bortezomib	22
Overall Study	COMPLETED	Bortezomib	21
Overall Study	NOT COMPLETED	Bortezomib	1

Source ClinicalTrials.gov

Adverse events133

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal pain	Gastrointestinal disorders	Bortezomib	1	22
other	Acidosis	Metabolism and nutrition disorders	Bortezomib	1	22
other	Alanine aminotransferase increased	Investigations	Bortezomib	3	22
other	Alkaline phosphatase increased	Investigations	Bortezomib	2	22
other	Anemia	Blood and lymphatic system disorders	Bortezomib	6	22
other	Anorexia	Metabolism and nutrition disorders	Bortezomib	7	22
other	Anxiety	Psychiatric disorders	Bortezomib	4	22
other	Arthralgia	Musculoskeletal and connective tissue disorders	Bortezomib	1	22
other	Arthritis	Musculoskeletal and connective tissue disorders	Bortezomib	1	22
other	Aspartate aminotransferase increased	Investigations	Bortezomib	1	22

1 to 10 of 133Source ClinicalTrials.gov

See all 133 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bortezomib
Total, other adverse events	Bortezomib	22	22
Total, serious adverse events	Bortezomib	17	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00104871

GET https://conductscience.org/api/trials/v1/NCT00104871/events?page=2

API reference For AI assistants